Matt Todd, Open Source chemistry for neglected diseases
David Shaywitz
Improved measurement: a path to better health for real people
The Open Science Summit unites researchers, life science industry professionals, students, patients and other stakeholders to discuss the future of collaborative science and innovation.
This, the second year, features in-depth sessions on new models for drug discovery and clinical trials, personal genomics, the patent system, the future of scientific publications, and more.
Bio
Barry Bunin Ph.D.
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen over $20 million in business transactions. Prior to CDD, Dr. Bunin was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Dr. Bunin led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry).
On the scientific side, he co-authored Chemoinformatics: Theory, Practice, and Products (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and The Combinatorial Index (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin is on a patent for Carfilzomib--a selective proteasome inhibitor now in phase 3 clinical trials for multiple myeloma.
Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.
Bernard Munos
Mr. Munos is the founder and chief apostle of InnoThink, a partnership dedicated to bringing evidence-based innovation models to the pharmaceutical industry and its stakeholders. Before that, he was advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policymakers, regulators, and patient advocates.
He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President's Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, Genome Canada, the American Chemical Society, and the Council for American Medical Innovation as well as leading universities and think-tanks in the U.S. and Europe.
He received his MBA from Stanford University and holds other graduate degrees in economics and animal science from the University of California at Davis and the Institut National Agronomique in Paris, France.
David Shaywitz Ph.D.
Dr. Shaywitz is a graduate of Harvard College (summa cum laude), and received his MD from the Health Sciences and Technology program at Harvard Medical School and MIT, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard.
He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group's Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco.
Dr. Shaywitz is a co-founder (with Dennis Ausiello) of the Harvard PASTEUR program, a translational research initiative at Harvard Medical School (www.pasteur.harvard.edu). He is also a founding advisor of Sage, a non-profit medical research initiative (founded by Eric Schadt and Stephen Friend) emphasizing networks and open innovation (www.sagebase.org).
For the last fifteen years, Dr. Shaywitz has contributed commentaries about medicine, science, innovation, and business to a number of popular publications, including The New York Times, The Washington Post, The Wall Street Journal, and The Financial Times. He currently is a regular contributor to Forbes.com.
Dr. Shaywitz is an Adjunct Scholar at the American Enterprise Institute.
Mat Todd Ph.D.
Mat Todd was born in Manchester, UK in 1973. He was educated at Cambridge University, and stayed there for a PhD with Professor Chris Abell where he worked on encoding and linker strategies for combinatorial chemistry. He received a Wellcome Trust International Travelling Research Fellowship for his postdoctoral studies with Professor Paul Bartlett at the University of California, Berkeley where he worked on divergent syntheses of peptidomimetic scaffolds.
He was appointed Fellow in Chemistry and College Lecturer at New Hall College, Cambridge in 2000, and then joined the faculty at Queen Mary, University of London in 2001. In 2005 he moved to the University of Sydney, where he is currently Senior Lecturer in Organic Chemistry.
